Exploring ischemic core growth rate and endovascular therapy benefit in large core patients.

IF 4.9 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Longting Lin, Yueming Wang, Chushuang Chen, Andrew Bivard, Kenneth Butcher, Carlos Garcia-Esperon, Neil J Spratt, Christopher R Levi, Xin Cheng, Qiang Dong, Mark W Parsons
{"title":"Exploring ischemic core growth rate and endovascular therapy benefit in large core patients.","authors":"Longting Lin, Yueming Wang, Chushuang Chen, Andrew Bivard, Kenneth Butcher, Carlos Garcia-Esperon, Neil J Spratt, Christopher R Levi, Xin Cheng, Qiang Dong, Mark W Parsons","doi":"10.1177/0271678X241242911","DOIUrl":null,"url":null,"abstract":"<p><p>After stroke onset, ischemic brain tissue will progress to infarction unless blood flow is restored. Core growth rate measures the infarction speed from stroke onset. This multicenter cohort study aimed to explore whether core growth rate influences benefit from the reperfusion treatment of endovascular thrombectomy in large ischemic core stroke patients. It identified 134 patients with large core volume >70 mL assessed on brain perfusion image within 9 hours of stroke onset. Of 134 patients, 71 received endovascular thrombectomy and 63 did not receive the treatment. Overall, poor outcomes were frequent, with 3-month severed disability or death rate at 56% in treatment group and 68% in no treatment group (p = 0.156). Patients were then stratified by core growth rate. For patients with 'ultrafast core growth' of >70 mL/hour, rates of poor outcome were especially high in patients without endovascular thrombectomy (n = 13/14, 93%) and relatively lower in patients received the treatment (n = 12/20, 60%, p = 0.033). In contrast, for patients with core growth rate <70 mL/hour, there was not a large difference in poor outcomes between patients with and without the treatment (55% vs. 61%, p = 0.522). Therefore, patients with 'ultrafast core growth' might stand to benefit the most from endovascular treatment.</p>","PeriodicalId":15325,"journal":{"name":"Journal of Cerebral Blood Flow and Metabolism","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cerebral Blood Flow and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/0271678X241242911","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

After stroke onset, ischemic brain tissue will progress to infarction unless blood flow is restored. Core growth rate measures the infarction speed from stroke onset. This multicenter cohort study aimed to explore whether core growth rate influences benefit from the reperfusion treatment of endovascular thrombectomy in large ischemic core stroke patients. It identified 134 patients with large core volume >70 mL assessed on brain perfusion image within 9 hours of stroke onset. Of 134 patients, 71 received endovascular thrombectomy and 63 did not receive the treatment. Overall, poor outcomes were frequent, with 3-month severed disability or death rate at 56% in treatment group and 68% in no treatment group (p = 0.156). Patients were then stratified by core growth rate. For patients with 'ultrafast core growth' of >70 mL/hour, rates of poor outcome were especially high in patients without endovascular thrombectomy (n = 13/14, 93%) and relatively lower in patients received the treatment (n = 12/20, 60%, p = 0.033). In contrast, for patients with core growth rate <70 mL/hour, there was not a large difference in poor outcomes between patients with and without the treatment (55% vs. 61%, p = 0.522). Therefore, patients with 'ultrafast core growth' might stand to benefit the most from endovascular treatment.

探索大核心患者的缺血核心生长率和血管内治疗的益处。
中风发生后,除非血流得到恢复,否则缺血性脑组织将发展为梗死。核心生长速度测量的是从脑卒中发生开始的梗死速度。这项多中心队列研究旨在探讨核心增长速度是否会影响大核心缺血性卒中患者从血管内血栓切除术再灌注治疗中获益。研究确定了 134 名在中风发生后 9 小时内通过脑灌注图像评估出大核心体积大于 70 毫升的患者。在 134 名患者中,71 人接受了血管内血栓切除术,63 人未接受治疗。总体而言,患者的预后较差,治疗组患者 3 个月后残疾或死亡的比例为 56%,未接受治疗组患者的比例为 68%(P = 0.156)。然后根据核心生长速度对患者进行分层。对于核心生长速度大于 70 毫升/小时的 "超快核心生长 "患者,未接受血管内血栓切除术的患者预后不佳的比例尤其高(n = 13/14,93%),而接受治疗的患者预后不佳的比例相对较低(n = 12/20,60%,p = 0.033)。相比之下,核心生长率
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cerebral Blood Flow and Metabolism
Journal of Cerebral Blood Flow and Metabolism 医学-内分泌学与代谢
CiteScore
12.00
自引率
4.80%
发文量
300
审稿时长
3 months
期刊介绍: JCBFM is the official journal of the International Society for Cerebral Blood Flow & Metabolism, which is committed to publishing high quality, independently peer-reviewed research and review material. JCBFM stands at the interface between basic and clinical neurovascular research, and features timely and relevant research highlighting experimental, theoretical, and clinical aspects of brain circulation, metabolism and imaging. The journal is relevant to any physician or scientist with an interest in brain function, cerebrovascular disease, cerebral vascular regulation and brain metabolism, including neurologists, neurochemists, physiologists, pharmacologists, anesthesiologists, neuroradiologists, neurosurgeons, neuropathologists and neuroscientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信